Zobrazeno 1 - 10
of 44
pro vyhledávání: '"D. J. Buchsbaum"'
Publikováno v:
ChemInform. 25
Publikováno v:
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). 44(3)
Utilization of molecular biology techniques offers attractive options in nuclear medicine for improving cancer imaging and therapy with radiolabeled peptides. Two of these options include utilization of phage-panning to identify novel tumor-specific
Autor:
F J, Kelly, C R, Miller, D J, Buchsbaum, J, Gomez-Navarro, M N, Barnes, R D, Alvarez, D T, Curiel
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(11)
Efficient gene transfer by recombinant adenovirus (Ad) vectors depends on expression of CAR and alpha(v) integrin on target cells. Because Ad may also infect nearby nontarget cells expressing these receptors, such as peritoneal mesothelial cells afte
Autor:
J A, Bonner, K P, Raisch, H Q, Trummell, F, Robert, R F, Meredith, S A, Spencer, D J, Buchsbaum, M N, Saleh, M A, Stackhouse, A F, LoBuglio, G E, Peters, W R, Carroll, H W, Waksal
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18
Epidermal growth factor receptor (EGFr) is overexpressed in a majority of head and neck squamous cell carcinomas, and this overexpression is associated with a poor prognosis. Therefore, EGFr has become the target of investigations aimed at disabling
Publikováno v:
Blood. 96(3)
Immunotoxin (IT) therapy shows potential for selectively eliminating GVHD-causing T cells in vivo, but the field has been hampered by toxicity. Previously, we showed that a genetically engineered IT consisting of a single-chain protein, including the
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 41(5)
Gene therapy protocols require better modalities to monitor the location and level of transferred gene expression. One potential in vivo mechanism to assess gene expression would be to image the binding of a radiolabeled peptide to a reporter recepto
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
One of the problems in achieving cures with radioimmunotherapy is that hematological toxicity limits the quantity of radiolabeled monoclonal antibody (MAb) that can be administered. The MAb CC49 binds with high affinity to the TAG-72 antigen expresse
Autor:
D J, Buchsbaum, B E, Rogers, M B, Khazaeli, M S, Mayo, D E, Milenic, S V, Kashmiri, C J, Anderson, L L, Chappell, M W, Brechbiel, D T, Curiel
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
Novel strategies to increase the therapeutic ratio in clinical radioimmunotherapy studies are needed. Limitations to radioimmunotherapy include bone marrow suppression due to the long circulating half-life of radiolabeled monoclonal antibodies (mAbs)
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
The trihydroxamate bifunctional chelating agent (BCA), trisuccin, has been shown to be a potential ligand for radiolabeling of monoclonal antibodies (MAbs) with rhenium radioisotopes, through an indirect postconjugation approach. The use of this trih
Autor:
B E, Rogers, S F, McLean, R L, Kirkman, D, Della Manna, S J, Bright, C C, Olsen, A D, Myracle, M S, Mayo, D T, Curiel, D J, Buchsbaum
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(2)
Adenoviral vectors, encoding genes for cell surface antigens or receptors, have been used to induce their high level expression on tumor cells in vitro and in vivo. These induced antigens and receptors can then be targeted with radiolabeled antibodie